Serum microRNA-92 expression in patients with ovarian epithelial carcinoma

Guo, Fengjun; Tian, Jingyan; Yang, Lin; Jin, Yishuai; Wang, Ling; Cui, Manhua

doi:10.1177/0300060513487652

Cited by 54 publications

(32 citation statements)

References 22 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, miRNA-based biomarkers have been proposed for several different cancer types including lung cancer, breast cancer, and gastrointestinal malignancies (10,11 ). For ovarian cancer, only 3 pilot studies so far have investigated miRNA candidates that are differentially expressed in ovarian cancer tissue or ovarian cancer cell lines for their presence in the circulation (12)(13)(14). Another study compared the expression pattern of exosomal, serum-derived miRNAs with the miRNA pattern of the corresponding primary tumor (15 ).…”

confidence: 99%

Circulating U2 Small Nuclear RNA Fragments as a Novel Diagnostic Tool for Patients with Epithelial Ovarian Cancer

et al. 2014

View full text Add to dashboard Cite

BACKGROUND Ovarian cancer is the leading cause of death among malignancies in women. Despite advances in treatment, >50% of patients relapse. For disease monitoring, the identification of a blood-based biomarker would be of prime interest. In this regard, noncoding RNAs, such as microRNA (miRNA) or small nuclear RNA (snRNA), have been suggested as biomarkers for noninvasive cancer diagnosis. In the present study, we sought to identify differentially expressed miRNA/snRNA in sera of ovarian cancer patients and investigate their potential to aid in therapy monitoring. METHODS miRNA/snRNA abundance was investigated in serum (n = 10) by microarray analysis and validated in an extended serum set (n = 119) by reverse-transcription quantitative PCR. RESULTS Abundance of U2-1 snRNA fragment (RNU2-1f) was significantly increased in sera of ovarian cancer patients (P < 0.0001) and paralleled International Federation of Gynecology and Obstetrics stage as well as residual tumor burden after surgery (P < 0.0001 and P = 0.011, respectively). Moreover, for patients with suboptimal debulking, preoperative RNU2-1f concentration was associated with radiographic response after chemotherapy and with platinum resistance (P = 0.0088 and P = 0.0015, respectively). Interestingly, according to the RNU2-1f abundance dynamics, persistent RNU2-1f positivity before surgery and after chemotherapy identified a subgroup of patients with high risk of recurrence and poor prognosis. CONCLUSIONS This is the first report to suggest that a circulating snRNA can serve as an auxiliary diagnostic tool for monitoring tumor dynamics in ovarian cancer. Our results provide a rationale to further investigate whether this high-risk patient group may benefit from additional therapies that are directly applied after chemotherapy.

show abstract

confidence: 99%

Circulating U2 Small Nuclear RNA Fragments as a Novel Diagnostic Tool for Patients with Epithelial Ovarian Cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Circulating microRNAs are highly tissue specific that can identify origin of metastasis and can be used as non-invasive biomarkers for cancers [22,30,31]. Several studies reported the association of circulating microRNAs with ovarian cancer detection, staging, grading of the disease, outcome and overall survival [32][33][34][35].…”

Section: Introductionmentioning

confidence: 99%

A novel serum microRNA panel to discriminate benign from malignant ovarian disease

et al. 2015

View full text Add to dashboard Cite

“…[8][9][10] MiRNAs are present in a stable form in human serum and plasma, suggesting the potential use of circulating miRNAs as stable blood-based markers for the detection of cancer or other human diseases. [11][12][13] MicroRNA-9 is upregulated in many tumour types including colorectal, 14 breast 15 and non-small cell lung cancer, 16 but its role in the progression of osteosarcoma remains unknown. The aim of this study, therefore, was to analyse the association between serum miR-9 concentrations and clinicopathological features and prognosis, in patients with osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Serum miR-9 as a prognostic biomarker in patients with osteosarcoma

et al. 2014

View full text Add to dashboard Cite

Objectives: To quantify microRNA-9 (miR-9) concentrations in the serum of patients with osteosarcoma; to explore its relationship with clinicopathological characteristics and prognosis of osteosarcoma. Method: Serum miR-9 was quantified via real-time reverse transcription-polymerase chain reaction in patients with osteosarcoma and healthy control subjects. Overall survival was evaluated using the Kaplan-Meier method. Results: Serum miR-9 was significantly upregulated in patients with osteosarcoma (n ¼ 118) compared with healthy control subjects (n ¼ 60); its upregulation was significantly associated with advanced tumour-node-metastasis stage, larger tumour size and presence of distant metastasis. Overall survival duration was significantly shorter in patients with relatively high miR-9 concentrations compared with those with relatively low miR-9 concentrations. Conclusions: Serum miR-9 concentrations are significantly increased in patients with osteosarcoma compared with healthy controls. Upregulation of miR-9 is associated with tumour stage, size and metastasis. Serum miR-9 quantification may represent a useful diagnostic and prognostic marker of osteosarcoma.

show abstract

Serum microRNA-92 expression in patients with ovarian epithelial carcinoma

Abstract: The detection of miR-92 levels in the serum might serve as a new tumour biomarker in the diagnosis and assessment of prognosis of EOC.

Cited by 54 publications

References 22 publications

Circulating U2 Small Nuclear RNA Fragments as a Novel Diagnostic Tool for Patients with Epithelial Ovarian Cancer

Circulating U2 Small Nuclear RNA Fragments as a Novel Diagnostic Tool for Patients with Epithelial Ovarian Cancer

A novel serum microRNA panel to discriminate benign from malignant ovarian disease

Serum miR-9 as a prognostic biomarker in patients with osteosarcoma

Contact Info

Product

Resources

About